Drugs / AR-105
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02486770 | Apr → Sep 2015 | — | Aridis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03027609 | Mar 2017 → Apr 2019 | pneumonia caused by pseudomonas aeruginosa infection | Aridis Pharmaceuticals, Inc. | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AR-105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03027609 ↗ |
| Known as | Aerucin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02486770 ↗ |
| Modality | Monoclonal antibody | “human monoclonal antibody (mAb) AR-105” NCT03027609 ↗ |
| Route | Intravenous | “IV Aerucin 2.0 mg/kg over 1 hour” NCT02486770 ↗ |